Seeking Alpha

Nektar receives $19.75M payment

  • Pursuant to its license, manufacturing and supply agreement with Ophthotech for certain aspects of its PEGylation technology to develop, manufacture and sell Fovista, Nektar Therapeutics (NKTR) receives a $19.75M payment from its partner.
  • On May 19, 2014 Ophthotech entered into a licensing and commercialization agreement with Novartis (NVS) for Fovista. Pursuant to this contract, Novartis paid Ophthotech a $200M upfront fee. This was the basis for paying $19.75M to NKTR.
  • NKTR is entitled to as much as $9.5M in additional payments from Ophthotech based on its achievement of certain regulatory and sales milestones plus low- to mid-single digit royalties on net sales of Fovista.
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (1491) | Send Message
    It's the year of NKTR.
    18 Jun, 06:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: